You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 254 No. 10, September 13, 1985 TABLE OF CONTENTS
  JAMA
  •  Online Features
  COUNCIL REPORT
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Status Report on the Acquired Immunodeficiency Syndrome

Human T-Cell Lymphotropic Virus Type III Testing

Council on Scientific Affairs

JAMA. 1985;254(10):1342-1345.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

HUMAN T-cell lymphotropic virus type III (HTLV-III) is a retrovirus that is currently accepted as the primary cause of the acquired immunodeficiency syndrome (AIDS). Serologic assays have been developed to detect the presence of antibody to HTLV-III; the presence of such antibodies is taken as reasonable proof of past or present infection with this agent. These assays have been used for epidemiologic studies and to screen defined populations and recently have been introduced for the screening of donated blood.

Recently the Food and Drug Administration (FDA) approved three test kits, manufactured by Abbott Laboratories, North Chicago, Ill, Electro-Nucleonics Inc, Fairfield, NJ, and Litton Bionetics, Charleston, SC, for screening donated blood and plasma for antibodies to HTLV-III. These kits utilize the enzyme-linked immunosorbent assay (ELISA) technique to detect antibodies to HTLV-III, which utilizes beads or microtiter wells coated with antigens obtained from disrupted whole virus grown in the human leukemic cell . . . [Full Text PDF of this Article]


Author Affiliations

From the Council on Scientific Affairs, Division of Scientific Activities, American Medical Association, Chicago.


Footnotes

This report is not intended to be construed or to serve as a standard of medical care. Standards of medical care are determined on the basis of all of the facts and circumstances involved in an individual case and are subject to change as scientific knowledge and technology advance and patterns of practice evolve. This report reflects the views of scientific literature as of June 1985.

Reprint requests to Division of Scientific Activities, Council on Scientific Affairs, American Medical Association, 535 N Dearborn St, Chicago, IL 60610 (John C. Ballin, PhD).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.